Similarly, recombinant T-cell receptor ligand-1000 (RTL1000) is an HLA-DR-derived peptide that binds CD74.177 RTL1000 has been studied in a Phase 1 clinical trial for multiple sclerosis, demonstrating favorable safety and tolerability.178 These results may inform preclinical and clinical studies in primary CNS tumors. This evidence concerns the gene CD74 and central nervous system neoplasm.